Table 6.
Possible prevalences (%) | ERI-2≥12 | ERI-2≥19 | ERI-2≥26 | ERI-2≥33 | ||||
Sensitivity 78.1% Specificity 79.7% |
Sensitivity 45.2% Specificity 92.6% |
Sensitivity 24.5% Specificity 98.0% |
Sensitivity 10.3% Specificity 100.0% |
|||||
PPV (%) | NPV (%) | PPV (%) | NPV (%) | PPV (%) | NPV (%) | PPV (%) | NPV (%) | |
2.0 | 7.3 | 99.4 | 11.1 | 98.8 | 20.0 | 98.5 | 29.6* | 98.2 |
1.0 | 3.7 | 99.7 | 5.8 | 99.4 | 11.0 | 99.2 | 17.2* | 99.1 |
0.5 | 1.9 | 99.9 | 3.0 | 99.7 | 5.8 | 99.6 | 9.4* | 99.5 |
0.1 | 0.4 | 100.0 | 0.6 | 99.9 | 1.2 | 99.9 | 2.0* | 99.9 |
Only participants with complete data for the predictors included in ERI-1 and ERI-2 (155 cases and 148 controls) were included in the analyses.
*PPV for ERI-2 cut-off ≥33 was calculated using a specificity of 99.5%, not 100.0%.
ERI-1, Endometriosis Risk Index Variant 1; ERI-2, Endometriosis Risk Index Variant 2; NPV, negative predictive value; PPV, positive predictive value.